Green tea, particularly its active ingredient (-)-epigallocatechin-3-O-gallate (EGCG), reduces the risk of cancer, liver disease and obesity, however, the precise mechanisms underlying these effects remain unclear. Herein, we examined the role of the myeloid cell 67-kDa laminin receptor (67LR) in mediating its physiological effects and demonstrated that the therapeutic effects of EGCG on liver fibrosis and obesity were attenuated in myeloid cell-specific 67LR knockout (67LRΔLysM) mice. EGCG treatment ameliorated liver fibrosis in the control 67LRfl/fl male mice but not in the 67LRΔLysM male mice. Next-generation sequencing revealed that EGCG regulates miRNA expression in macrophages through the 67LR. Our results elucidated the anti-inflammatory mechanisms of EGCG through a transcriptomic analysis of adipose tissues. In addition, EGCG supplementation suppressed macrophage recruitment, glucose intolerance, and adipose inflammation in the control 67LRfl/fl male mice, but not in the 67LRΔLysM male mice. In conclusion, EGCG exerts antifibrotic and antiobesity effects mediated by the 67LR.
No takes yet. Share an insight, caveat, or question.
Kumazoe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: